Search results
Novel Agent Curbs Alzheimer's-Related Agitation
Medscape· 6 days agoTreatment with AXS-05, a combination of dextromethorphan and bupropion, demonstrated rapid, sustained, and clinically meaningful improvement in agitation...
Bright Light, Sharper Mind: Lighting Affects Cognition - Neuroscience News
Neuroscience News· 5 days agoThe study utilized advanced 7 Tesla fMRI to show that higher levels of light improve cognitive...
Napper or love a lie-in? Your guide to sleeping better, according to your sleep type
The Telegraph via Yahoo News· 13 hours agoThese findings chime with a 2018 study from Western University in Ontario, which showed that those...
Does a woman's heart health affect cognition in midlife?
Medical Xpress· 5 days agoCognition (measured as processing speed and working memory) was assessed annually or biennially over...
Trump's criminal trials are accelerating the countdown clock on America's news media
Salon via Yahoo News· 2 days agoHowever, Donald Trump’s worsening and much more severe challenges in memory, speech, cognition, and...
Poor heart health in midlife can harm cognition in Black women
Medical News Today· 4 days agoBlack women with heart health issues may experience earlier cognitive decline, according to a new...
Parkinson's: New treatment may help reduce motor symptoms
Medical News Today· 4 days agoPrasinezumab, a monoclonal antibody designed to target protein clumps in the brains of people with...
Beta Rhythms May Be Master Regulators of Cognitive Control - Neuroscience News
Neuroscience News· 5 days agoSummary: A new study highlights the critical role of beta rhythms (14-30 Hz) in orchestrating...
Can supplements really help prevent dementia?
The Telegraph via Yahoo News· 6 days agoBy 2025, it’s estimated that over one million people in the UK will have a diagnosis of dementia. It’s a sobering thought, but new research suggests that...
Enrolment completed in Actinogen's XanaCIDD phase 2a cognition & depression trial
WTNH-TV New Haven· 7 days agoActinogen Medical Limited (ASX: ACW) announces the full enrolment of 167 participants in the Company's XanaCIDD phase 2a clinical trial in patients with cognitive impairment in major depressive ...